Head-To-Head Analysis: GT Biopharma (NASDAQ:GTBP) versus Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) and GT Biopharma (NASDAQ:GTBP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Profitability

This table compares Insmed and GT Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insmed	-244.27%	N/A	-57.00%
GT Biopharma	N/A	-171.45%	-98.14%

Valuation & Earnings

This table compares Insmed and GT Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$328.61 million	34.66	-$749.57 million	($5.23)	-14.66
GT Biopharma	N/A	N/A	-$7.60 million	N/A	N/A

GT Biopharma has lower revenue, but higher earnings than Insmed.

Risk & Volatility

Insmed has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Insmed and GT Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	0	0	16	0	3.00
GT Biopharma	0	0	0	0	N/A

Insmed presently has a consensus price target of $82.73, indicating a potential upside of 7.94%. Given Insmed’s higher possible upside, equities research analysts clearly believe Insmed is more favorable than GT Biopharma.

Institutional and Insider Ownership

8.1% of GT Biopharma shares are held by institutional investors. 4.6% of Insmed shares are held by company insiders. Comparatively, 10.0% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Insmed beats GT Biopharma on 6 of the 10 factors compared between the two stocks.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

About GT Biopharma

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.